312 related articles for article (PubMed ID: 25610811)
1. Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines.
Graner MW; Lillehei KO; Katsanis E
Front Oncol; 2014; 4():379. PubMed ID: 25610811
[TBL] [Abstract][Full Text] [Related]
2. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
3. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure.
Mayer-Sonnenfeld T; Har-Noy M; Lillehei KO; Graner MW
Int J Hyperthermia; 2013 Sep; 29(6):520-7. PubMed ID: 23734882
[TBL] [Abstract][Full Text] [Related]
5. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.
Graner MW; Romanoski A; Katsanis E
Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.
Graner MW; Zeng Y; Feng H; Katsanis E
Cancer Immunol Immunother; 2003 Apr; 52(4):226-34. PubMed ID: 12669247
[TBL] [Abstract][Full Text] [Related]
7. [Endoplasmic Reticulum Chaperones at the Tumor Cell Surface and in the Extracellular Space].
Brychtová V; Vojtěšek B
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):25-30. PubMed ID: 27846717
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
Lin CT; Chang TC; Chao A; Dzeng E; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2005; 12(2):279-87. PubMed ID: 15918000
[TBL] [Abstract][Full Text] [Related]
9. Control of MHC class I traffic from the endoplasmic reticulum by cellular chaperones and viral anti-chaperones.
Gruhler A; Früh K
Traffic; 2000 Apr; 1(4):306-11. PubMed ID: 11208115
[TBL] [Abstract][Full Text] [Related]
10. To find the road traveled to tumor immunity: the trafficking itineraries of molecular chaperones in antigen-presenting cells.
Berwin B; Nicchitta CV
Traffic; 2001 Oct; 2(10):690-7. PubMed ID: 11576445
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity.
Wiersma VR; Michalak M; Abdullah TM; Bremer E; Eggleton P
Front Oncol; 2015; 5():7. PubMed ID: 25688334
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex class I-restricted antigen processing and presentation.
Van Kaer L
Tissue Antigens; 2002 Jul; 60(1):1-9. PubMed ID: 12366777
[TBL] [Abstract][Full Text] [Related]
13. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.
Li G; Zeng Y; Chen X; Larmonier N; Sepassi M; Graner MW; Andreansky S; Brewer MA; Katsanis E
Clin Exp Immunol; 2007 Apr; 148(1):136-45. PubMed ID: 17349014
[TBL] [Abstract][Full Text] [Related]
14. Chaperones and folding of MHC class I molecules in the endoplasmic reticulum.
Paulsson K; Wang P
Biochim Biophys Acta; 2003 Jun; 1641(1):1-12. PubMed ID: 12788224
[TBL] [Abstract][Full Text] [Related]
15. Roles of molecular chaperones in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD).
Nishikawa S; Brodsky JL; Nakatsukasa K
J Biochem; 2005 May; 137(5):551-5. PubMed ID: 15944407
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of MHC class I-antigen processing: redox considerations.
Kim Y; Kang K; Kim I; Lee YJ; Oh C; Ryoo J; Jeong E; Ahn K
Antioxid Redox Signal; 2009 Apr; 11(4):907-36. PubMed ID: 19178136
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum chaperones and oxidoreductases: critical regulators of tumor cell survival and immunorecognition.
Gutiérrez T; Simmen T
Front Oncol; 2014; 4():291. PubMed ID: 25386408
[TBL] [Abstract][Full Text] [Related]
18. The immunological properties of endoplasmic reticulum chaperones: a conflict of interest?
Nicchitta CV; Reed RC
Essays Biochem; 2000; 36():15-25. PubMed ID: 12471899
[TBL] [Abstract][Full Text] [Related]
19. Endoplasmic reticulum-resident chaperones modulate the inflammatory and angiogenic responses of endothelial cells.
Tsaryk R; Bartholomä NM; Simiantonaki N; Anspach L; Peters K; Heilmann C; Kirkpatrick CJ; Pröls F
Br J Dermatol; 2015 Aug; 173(2):416-27. PubMed ID: 25832777
[TBL] [Abstract][Full Text] [Related]
20. The cell biology of MHC class I antigen presentation.
Williams A; Peh CA; Elliott T
Tissue Antigens; 2002 Jan; 59(1):3-17. PubMed ID: 11972873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
